CoChat
Sign Up
Cited by 372Reproductive Biology and FertilityOvarian function and disordersReproductive Health and Technologies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report

Goswami, S.K.·2004·Human Reproduction
DOI 10.1093/humrep/deh359
Open this paper in CoChat — free account

Abstract

BACKGROUND: Use of letrozole, a selective inhibitor of aromatase, reduces the gonadotrophin dose required to induce follicular maturation. We evaluated whether incorporation of letrozole could be an effective low-cost IVF protocol for poor responders. METHODS: A randomized, controlled, single-blind trial was conducted in the Assisted Reproduction Unit, Institute of Reproductive Medicine, Kolkata, India. Thirty-eight women with a history of poor ovarian response to gonadotrophins were recruited. Thirteen women (Let-FSH group) received letrozole 2.5 mg daily from day 3-7, and recombinant FSH (rFSH) 75 IU/day on days 3 and 8; and 25 women (GnRH-ag-FSH group) underwent long GnRH agonist protocol and stimulated with rFSH (300-450 IU/day). Ovulation was triggered by 10,000 IU of HCG followed by IVF-embryo transfer. The main outcome measures were total dose of rFSH (IU/cycle), terminal estradiol (E2) (pg/ml), numbers of follicles, oocytes retrieved and transferable embryo, endometrial thickness (mm), and pregnancy rate. RESULTS: Compared with the GnRH-ag-FSH group (2865 +/- 228 IU), the Let-FSH group (150 +/- 0 IU) received a significantly (P < 0.001) lower total dose of FSH. Except for terminal E2, which was significantly higher (P < 0.001) in the GnRH-ag-FSH group (380 +/- 46 pg/ml) than the Let-FSH group (227 +/- 45 pg/ml), the treatment outcomes in all other respects, including pregnancy rate, were statistically comparable. CONCLUSIONS: Adjunctive use of letrozole may form an effective means of low-cost IVF protocol in poorly responding women.

Overview

Integrity signals

Registry

Crossref · 10.1093/humrep/deh359

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 31 references

Cited by

Sorted by citations

Items 301–372 of 372

Related

See all

Metadata

Authors
Goswami, S. K.
Affiliations
Institute of Reproductive Medicine (IN)
Corresponding author
Goswami, S.K.
ORCID
Goswami, S.K.
Venue
Human Reproduction
Publisher
Oxford University Press (OUP)
Published
2004-06-24
Volume
19
Issue
9
Pages
2031-2035
ISSN
  • 0268-1161 (ISSN-L)
  • 1460-2350
DOI
10.1093/humrep/deh359
OpenAlex
W2105251513
Cited by
372
References
31
Citations by year
2025: 5 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 10 · 2018: 5 · 2017: 40 · 2016: 12 · 2015: 44 · 2014: 37 · 2013: 33 · 2012: 36
FWCI
8.53
Type
journal article
Language
en
Open access
closed
Locations
  • Human Reproduction (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
Keywords
letrozole, poor ovarian response, aromatase inhibitors, recombinant FSH, GnRH agonist protocol, oocyte retrieval, pregnancy rate
MeSH terms
Letrozole, Adult, Cost Control, Dose-Response Relationship, Drug, Drug Resistance, Embryo Transfer, Estradiol, Female, Fertilization in Vitro, Follicle Stimulating Hormone, Gonadotropins, Chorionic Gonadotropin, Humans, Gonadotropin-Releasing Hormone, Nitriles, Ovary, Pregnancy, Recombinant Proteins, Triazoles, Single-Blind Method, Treatment Outcome, Pregnancy Rate, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review